References
Robak T, Matutes E, Catovsky D et al (2015) Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v100–v107
Goede V, Fischer K, Busch R et al (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110
Sehn LH, Chua NS, Mayer J (2015) GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared to bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphomas. J Clin Oncol 33(Supplement):LBA8502
Freeman CL, Dixon M, Houghton R (2014) Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: analysis of the CLL11 study dataset. Blood 124(Supplement):3339
Ginaldi L, De MM, Matutes E et al (1998) Levels of expression of CD19 and CD20 in chronic B-cell leukaemias. J Clin Pathol 51:364–369
Funding
This work was not supported by any grants.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from the patient for publication of this case report.
Rights and permissions
About this article
Cite this article
Bohn, JP., Willenbacher, E. & Steurer, M. Obinutuzumab in multidrug-resistant hairy cell leukemia. Ann Hematol 95, 351–352 (2016). https://doi.org/10.1007/s00277-015-2520-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-015-2520-y